No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SCYX250117P5000
- 0.00
- 0.000.00%
15min DelayClose Jan 3 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover352.83%IV-254.61%PremiumJan 17, 2025Expiry Date3.59Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9549Delta0.1178Gamma0.39Leverage Ratio-0.0030Theta-0.0008Rho-0.37Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
No Data
News
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Express News | Scynexis Initiates Dosing in Phase 1 Trial of Scy-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
US Manufacturing Index Rises To 43, Highest Since 2020
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $8
SCYNEXIS's Strong Financial Position and Strategic Advancements Drive Buy Rating